PreveCeutical Welcomes Stephen Glover as Corporate Advisor

Vancouver, British Columbia--(Newsfile Corp. - May 26, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that Steve Glover has been appointed as Corporate Advisor effective on 24 May, 2025.

Stephen Van Deventer, CEO of PreveCeutical, commented:

"We are honoured to welcome Stephen Glover as our Corporate Advisor. Stephen's proven leadership in biopharma, combined with his expertise in corporate strategy, commercialization, and financial management, makes him an invaluable addition to our team. His track record of building and transforming organizations aligns seamlessly with PreveCeutical's mission to advance groundbreaking therapies."

About Stephen Glover:

Stephen Glover is an accomplished executive with over three decades of leadership experience in the biopharma industry. Currently, he serves as Chairman and CEO of ZyVersa Therapeutics, a clinical-stage specialty biopharmaceutical company focused on innovative treatments for inflammatory and kidney diseases. Stephen has successfully led multiple organizations, securing over $500 million in capital and creating more than $7 billion in shareholder value.

Previously, Stephen was Chairman of Ambrx, overseeing its $2 billion acquisition by Johnson & Johnson. He also co-founded Coherus BioSciences, where he developed strategic partnerships valued at over $300 million. Stephen's operational expertise spans commercialization, integrated product development, and governance, having overseen the launch of over 25 products in multiple therapeutic areas.

In addition to his extensive executive experience, Stephen serves on the board of publicly traded companies, including as Chairman of PDS Biotechnology, a NASDAQ company and the University of Miami Coulter Foundation, bringing insights into audit, compensation, and governance practices.

Stephen Glover remarked on his appointment:

"I am excited to join PreveCeutical and work with the leadership team to expand the application and growth of their exciting Sol-Gel program in multiple therapeutic categories. The growth of the nasal delivery market over the next few years represents a great opportunity to develop new products for significant unmet medical needs and provide patients with a better option for treatments in many disease areas."

About PreveCeutical Medical Inc.

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.

On Behalf of the Board of Directors,
PreveCeutical Medical Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer

Forward-Looking Statements:

This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, the continued research interests of PreveCeutical, PreveCeutical's anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical's research and development activities, performance, industry trends, growth opportunities, that PreveCeutical will be granted requisite expedited approvals by world health, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities.

Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and obtaining expedited requisite approvals from world health agencies; and the ability of PreveCeutical to commercialize products, pursue business partnerships, complete their research programs as planned, and obtain the financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical's filings are available at www.sedar.com. Neither the Canadian Securities Exchange (CSE or CNSX Markets), its Regulation Services Provider (as that term is defined in policies of the CSE), nor any other regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Any link in this press release to external information or other resources is provided for reference only, and such information or resources might change from time to time, and may include forward-looking statements as described above, and are subject to the above disclaimers under this heading forward-looking statements.

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253362